Published: Jan 08, 2021
SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ Nearly all cancer patients face fear, anxiety, and uncertainty following diagnosis and treatment. Cancer-related distress can impact a patient s emotional and physical well-being, which for many has been further compounded by the COVID-19 pandemic. Founded by a team of biotech veterans, Blue Note Therapeutics, Inc., is leveraging deep scientific and clinical expertise, neuroscience, and digital innovation to make mental health care available to any cancer patient at any time. In 2020, the company launched
COVID Cancer Care, a digital program intended to help adults with cancer cope with stress and anxiety related to the COVID-19 pandemic.
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths Written By:ACS Medical Content and News Staff January 12, 2021
The death rate from cancer in the United States has continued to decline. From 1991 to 2018, the cancer death rate has fallen 31%. This includes a 2.4% decline from 2017 to 2018 – a new record for the largest one-year drop in the cancer death rate. These are just some of the findings from the annual statistics reported by the American Cancer Society (ACS).
In Cancer Statistics, 2021 and its consumer-friendly companion,
Cancer Facts & Figures 2021, ACS researchers estimate that in the US in 2021, almost 1.9 million new cancer cases will be diagnosed. And more than 600,000 people will die from cancer.
Search jobs 08-Jan-2021 U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
Phase III data showed treatment with NUBEQA resulted in a 31% reduction in risk of death, with a statistically significant improvement in overall survival (OS) compared to placebo (HR=0.69, 95% CI 0.53-0.88; p=0.003), giving men with non-metastatic castration-resistant prostate cancer (nmCRPC) the opportunity to extend their lives
1
Time to pain progression, a key secondary endpoint, is meaningful for men living with nmCRPC and an important consideration in treatment decisions
1
1,2
WHIPPANY, N.J. (BUSINESS WIRE) Bayer today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to add overall survival (OS) and other secondary endpoint data from the Phase III ARAMIS trial to the NUBEQA
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DUBLIN, Dec. 21, 2020 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to
E. coli-derived asparaginase.
The BLA was initiated and will be reviewed under the Real-Time Oncology Review (RTOR) pilot program, an initiative of the FDA s Oncology Center of Excellence designed to expedite the delivery of safe and effective cancer treatments to patients.